- •Ocular Blood Flow
- •Contents
- •1: Anatomy of the Ocular Vasculatures
- •Core Messages
- •1.1 Limbus and Conjunctiva
- •1.1.1 Cornea
- •1.1.2 Vasculature Distribution in the Anterior Segment
- •1.1.3 The Conjunctiva
- •1.1.3.1 The Conjunctival Arterial Supply
- •1.1.3.2 The Conjunctival Veins
- •1.2 Uveal Tract
- •1.2.1 The Iris
- •1.2.1.1 The Major Arterial Circle of the Iris
- •1.2.2 Ciliary Body and Processes
- •1.2.3 Choroid and Suprachoroid
- •1.2.3.1 Development of the Choroidal Vasculature
- •1.2.3.2 Arteries
- •1.2.3.3 Choroidal Veins (Vortex Veins)
- •1.2.3.4 Choriocapillaris
- •1.3 Optic Nerve Vasculature
- •1.4 Retina
- •1.4.1 Development of the Retinal Vasculature
- •1.4.2 Adult Retinal Vasculature
- •1.4.3 Nonprimate Adult Retinal Vasculatures
- •1.5 Conclusions
- •References
- •Core Messages
- •2.1 Introduction
- •2.3 Stochastic Error in the Entrapment of Microspheres
- •2.4 Methodological Errors and Practical Advice
- •2.4.1 Size of the Microspheres
- •2.4.2 Physical Characteristics of Microspheres
- •2.4.4 Dissection
- •2.4.5 Detection of RM and NAM
- •2.4.6 Detection of CM and FM
- •2.5 Biological Variation
- •2.5.1 Blood Pressure
- •2.5.3 Arterial Blood Gases
- •2.5.4 Other Possible Causes for Biological Variability
- •2.6 Summary for the Clinician
- •References
- •3: Laser Doppler Flowmetry in Animals
- •Core Messages
- •3.1 Introduction
- •3.2 History
- •3.3 Theory
- •3.4 Validation
- •3.5 Calibration
- •3.6 Zero Offset
- •3.7 Effects of Oxygen
- •3.9 Measurement Depth and Sampling Volume
- •3.10 Caveats
- •References
- •4: Oxygen Measurements in Animals
- •Core Messages
- •4.1 Introduction
- •4.2.1 Oxygen Electrodes
- •4.2.2 Hypoxyprobe
- •4.2.3 Magnetic Resonance Imaging
- •4.2.4 Phosphorescence Decay
- •4.2.5 Oximetry
- •4.3.1 Vitreal Oxygen
- •4.3.2 Intraretinal Oxygen
- •4.4 Oxygen in Avascular Retinas
- •4.5 Analysis of Retinal Oxygen Utilization
- •4.5.1 Fick Principle Analyses
- •4.5.4 Other Diffusion Models
- •4.6 Physiological Variations in Retinal Oxygen
- •4.6.1 Light
- •4.6.2 Hypoxia
- •4.6.3 Hyperoxia
- •4.6.4 Hypercapnia
- •4.7 Pathophysiology and Retinal Oxygen
- •4.7.1 Vascular Occlusion
- •4.7.2 Diabetes
- •4.7.3 Retinal Detachment
- •4.7.4 Retinal Degenerative Diseases
- •4.7.5 Retinopathy of Prematurity
- •4.8 Retinal Molecular Changes Related to Oxygen
- •4.9 Oxygen in the Optic Nerve Head
- •References
- •Core Messages
- •5.1 Measuring Technique
- •5.2 Normal Values
- •5.3 Retinal Pathologies
- •5.3.1 Diabetes Mellitus
- •5.3.2 Central Retinal Vein Occlusion
- •5.4 Summary
- •References
- •Core Messages
- •6.1 Introduction
- •6.1.1 Anatomy
- •6.3 Vessel Diameter Measurements Based on Photographic and Digitally Stored Images
- •6.3.1 Basics for Measurements on Stored Images
- •6.3.1.1 Measuring Principle
- •6.3.1.4 Problems and Measuring Errors
- •6.3.1.5 Physiological Variability of Vessel Diameter
- •6.3.2 Methods
- •6.3.2.2 Microdensitometry Based on Photographic Negatives
- •6.3.2.3 Measurements Based on Digital Images
- •6.4 Diameter Assessment for Blood Flow
- •6.4.1 Assessment of Flow by Use of Doppler Technique (CLBF)
- •6.5 Retinal Vessel Analysis
- •6.5.1 Basics of Retinal Vessel Analysis
- •6.5.2 Static Vessel Analysis
- •6.5.3 Results and Limits of Static Vessel Analysis
- •6.5.4 Results and Limits of Dynamic Vessel Analysis
- •6.5.4.1 Stimulation with Flicker Light
- •6.5.4.2 Other Provocation Tests
- •6.5.5 Systems Available for Dynamic Vessel Analysis
- •6.6 Further Perspectives
- •References
- •Core Messages
- •7.1 Introduction
- •7.2 Retinal Laser Doppler Velocimetry
- •7.2.1 The Doppler Effect
- •7.2.2 Electric Field Scattered by Singly Scattering Particles Moving in a Capillary Tube
- •7.2.5 Experimental Test of the Bidirectional LDV Technique
- •7.2.7 The DSPS for RBCs Moving in a Retinal Vessel
- •7.2.7.1 Multiple Scattering of Blood
- •7.2.7.2 DSPS from RBCs Flowing in a Glass Capillary Tube
- •7.2.7.3 DSPS from Human Retinal Vessels
- •7.2.7.4 Exploring the Scattering Process
- •7.2.9 Instrumentation
- •7.2.10 Blood Flow in Retinal Vessels
- •7.2.12 Limitations, Safety, and Future Directions of the LDV Technique
- •7.2.13 Physiologic and Clinical Applications (Brief Overview)
- •7.3.1 The DSPS for RBCs Moving in the Microvascular Bed of a Tissue
- •7.3.2 Hemodynamic Parameters Derived from the DSPS
- •7.3.3 Detection Scheme for Optic Nerve and Subfoveal Choroidal Blood Flow
- •7.3.4 Critical Questions Regarding the Application of LDF to Ocular Blood Flow
- •7.3.4.1 LDF Sample Volume
- •7.3.4.2 Linearity of LDF
- •7.3.4.3 Scattering Scheme
- •7.3.5 Reproducibility of LDF
- •7.3.6 Applications of LDF
- •7.4 Summary for the Clinician
- •References
- •8: Color Doppler Imaging
- •Core Messages
- •8.1 Principles
- •8.2 Instrumentation
- •8.3 Procedure
- •8.4 Outcome Variables
- •8.5 Reproducibility
- •8.6 Physiological and Pharmacological Stimuli
- •8.7 Results in Patients with Disease
- •8.8 Advantages and Limitations
- •References
- •9: Other Approaches
- •Core Messages
- •9.1 Blue Field Entoptic Technique
- •9.1.1 Laser Speckle Technique
- •9.1.2 Pulsatile Ocular Blood Flow
- •9.1.2.1 Laser Interferometry
- •References
- •10: Systemic Determinants
- •Core Messages
- •10.1 Introduction
- •10.1.1 Ocular and Systemic Blood Flow
- •10.2 Local Skin Cooling Effect
- •10.2.1 Choroidal Blood Flow
- •10.2.2 Retinal Blood Flow
- •10.3 Aerobic Exercise
- •10.3.1 Choroidal Blood Flow
- •10.3.2 Macular Blood Flow
- •10.3.3 Retinal Blood Flow
- •10.4 Neural Activation
- •10.4.1 Valsalva Maneuver
- •10.4.2 Nicotine
- •10.5 Blood Pressure Versus Ocular Perfusion Pressure
- •10.5.1 Increased Ocular Perfusion Pressure
- •10.5.1.1 Choroidal Blood Flow
- •10.5.2 Decreased Ocular Perfusion Pressure
- •10.5.2.1 Choroidal Blood Flow
- •10.5.2.2 Optic Nerve Head Blood Flow
- •10.5.3 Neural Retinal Function
- •10.6 Blood Gases
- •10.6.1 Hyperoxia and Blood Flow
- •10.6.3 Hypoxia and Pulsatile Choroidal Blood Flow
- •10.6.4 Hyperoxia, Hypercapnia, and Retinal Function
- •10.6.5 Hypoxia, Hyperoxia, and Retinal Function
- •10.7 Regional Choroidal Perfusion
- •10.7.1 Cones Versus Rods: Structure and Function
- •10.7.2 Choroidal Angioarchitecture
- •10.7.3 Dark Adaptation
- •10.7.4 Protracted Blue Flicker
- •10.8 Aging
- •10.8.1 Structure
- •10.8.2 Blood Flow
- •10.8.3 Retinal Function
- •References
- •11: Local Determinants
- •Core Messages
- •11.1 Introduction
- •11.2 Ocular Perfusion Pressure, IOP, and the Ocular Starling Resistor Effect
- •11.3 Types of Local Control
- •11.3.1 Myogenic Local Control
- •11.3.2 Metabolic Local Control
- •11.3.3 Flow-Mediated Vasodilation
- •11.3.4 Flow Control by Intercellular Conduction
- •11.4 Ocular Local Control
- •11.4.1 Optic Nerve Head (ONH)
- •11.4.2 Choroid
- •11.4.3 Retina
- •11.4.4 Ciliary Body
- •11.4.5 Iris
- •11.5 Caveats
- •11.6 Summary for the Clinician
- •References
- •12: Neural Control of Ocular Blood Flow
- •Core Messages
- •12.1 Overview of Ocular Blood Supplies and Their Neural Control
- •12.2 Neural Control of Optic Nerve and Retinal Blood Flow
- •12.3 Neural Control of Iridial and Ciliary Body Blood Flow
- •12.4 Neural Control of Blood Flow in Orbital Glands
- •12.5 Neural Control of Choroidal Blood Flow
- •12.5.1 Importance of the Choroid
- •12.5.2 Choroidal Innervation: Overview of Anatomy
- •12.5.3 Facial Nucleus Parasympathetic Input
- •12.5.3.4 Choroidal Autoregulation and the PPG Input to Choroid – Mammals
- •12.5.3.8 Choroidal Autoregulation and the PPG Input to Choroid – Birds
- •12.5.4 Oculomotor Nucleus Parasympathetic Input
- •12.5.4.1 Ciliary Ganglion Circuitry – Mammals
- •12.5.4.2 Function of the EW-Ciliary Ganglion Circuit – Mammals
- •12.5.4.3 Ciliary Ganglion Circuitry – Birds
- •12.5.4.4 Function of vSCN-EWM-Ciliary Ganglion Circuit – Birds
- •12.5.5 Sympathetic Superior Cervical Ganglion Input
- •12.5.6 Trigeminal Sensory Input
- •12.5.7 Intrinsic Choroidal Neurons
- •12.5.8 Disturbed Neural Control of Choroidal Blood Flow in Aging and Retinal Disease
- •12.5.8.1 Effect of Aging on Retina and Choroid
- •12.5.8.2 Effect of Disease on Retina and Choroid
- •References
- •13: Endothelial and Adrenergic Control
- •Core Messages
- •13.1 Nitric Oxide
- •13.2 Endothelins
- •13.3 Arachidonic Acid Metabolites
- •13.4 Adrenergic Control
- •13.5 Alpha Receptors
- •13.6 Topical Administration
- •13.6.1 Clonidine
- •13.6.2 Brimonidine
- •13.6.3 Beta Receptors
- •13.6.4 Timolol
- •13.6.5 Human Studies
- •13.6.6 Betaxolol
- •13.6.7 Human Studies
- •13.6.8 Levobunolol
- •13.6.9 Carteolol
- •13.6.10 Serotonin
- •13.7 Carbonic Anhydrase Inhibitors
- •13.8 Acetazolamide
- •13.9 Dorzolamide
- •13.10 Retrobulbar Blood Flow
- •13.11 Retinal Blood Flow
- •13.12 Choroidal and Optic Nerve Head Blood Flow
- •13.13 Brinzolamide
- •References
- •Core Messages
- •14.1 Introduction
- •14.2 Retinal Ischemia Basic Mechanisms
- •14.3 Oxidative Stress
- •14.6 Animal Studies Relating Ischemia, Glaucoma, and Neuroprotection
- •14.6.1 Retinal Ischemia
- •14.6.6 Role of Mitochondria (Fig. 14.6)
- •References
- •Core Messages
- •15.1 Introduction
- •15.2 Retinal Blood Flow in Diabetes
- •15.3 Retinal Hypoperfusion
- •15.3.1 Mechanisms of Hypoperfusion
- •15.3.1.1 Glycaemic Control
- •15.3.1.2 Protein Kinase C
- •15.3.1.3 Ion Channel Dysfunction
- •15.4 Retinal Hyperperfusion
- •15.4.1 Mechanisms of Hyperperfusion: A Link to Hypoperfusion, Tissue Hypoxia and Retinal Leukostasis?
- •15.4.2 Retinal Autoregulation in Diabetes
- •15.5.1 Basement Membrane Thickening
- •15.5.3 Microaneurysms
- •15.5.4 Capillary Acellularity
- •15.6 Retinal Blood Flow and Vision Loss in Diabetic Retinopathy
- •15.6.1 Diabetic Macular Oedema
- •15.6.2 Proliferative Diabetic Retinopathy
- •15.7 Conclusions
- •15.8 Summary for the Clinician
- •References
- •Core Messages
- •16.1 Introduction
- •16.2 Choroidal Blood Flow
- •16.3 Systemic Vascular Factors and AMD
- •16.5 Choroidal Hemodynamic Changes in AMD
- •16.5.1 Choroidal Histopathological Vascular Changes in AMD
- •16.5.1.1 Choriocapillaris and Bruch’s Membrane in Aging and AMD
- •16.5.2 Choroidal Microcirculation in AMD
- •16.5.2.2 Choroidal Watershed Zones and Neovascularization
- •16.5.2.3 Laser Doppler Flowmetry Evaluation
- •References
- •Core Messages
- •17.1 Introduction
- •17.2 Potential Mechanisms of Ischaemic Damage in Glaucoma
- •17.2.2 Autoregulatory Disturbances
- •17.2.3 Mechanical Compression or Collapse of Vessels
- •17.2.4 Atherosclerosis
- •17.2.5 Vascular Endothelial Factors
- •17.2.6 Barriers to Nutrient Delivery
- •17.2.7 Circulating Vasoconstrictors
- •17.3 Evidence Base Supporting the Importance of Ischaemia in Glaucoma
- •17.3.1 Association and Causality
- •17.3.1.1 Reduction in Optic Nerve Head Blood Flow
- •17.3.1.2 Blood Pressure, Intraocular Pressure and Perfusion Pressure
- •17.3.1.3 Nocturnal Hypotension
- •17.3.1.4 Vasospasm
- •17.3.1.5 Endothelin and Other Circulating Peptides
- •17.3.2 Effects of Treatment
- •17.3.2.1 Calcium Channel Blockers
- •17.3.2.2 Topical Adrenergic Antagonists
- •17.3.2.4 Prostaglandin Analogues
- •17.4 Experimental Models of Ischaemia Relating to Glaucoma
- •17.4.1 Acute Ischaemia
- •17.4.2 Chronic Ischaemia
- •17.5 Summary
- •17.5.1 Diversity of Evidence
- •17.5.2 Evidence Base Compared to Intraocular Pressure
- •17.5.3 Requirements to Strengthen Evidence Base
- •References
- •Core Messages
- •18.1 Retinal Diseases
- •18.2 Uveitis
- •18.3 Optic Nerve Disorders
- •18.4 Systemic Diseases
- •References
- •Core Messages
- •19.1 Atherosclerosis
- •19.1.1 Pathogenesis of Atherosclerosis
- •19.1.2 Internal Carotid Artery Disease (ICA)
- •19.1.3 Effects on the Ocular Circulation
- •19.1.3.1 Retinal Artery Occlusion
- •Clinical Characteristics
- •Diagnosis
- •Mortality/Morbidity
- •19.1.3.2 Retinal Vein Occlusion (RVO)
- •Clinical Characteristics
- •Pathogenesis
- •Diagnosis
- •19.1.3.3 Ischemic Optic Neuropathy
- •Clinical Characteristics
- •Mortality/Morbidity
- •19.1.3.4 Asymptomatic Retinal Emboli
- •Background
- •Pathophysiology
- •19.2 Vasculitis
- •19.2.1 Takayasu’s Arteritis (Aortic Arch Syndrome)
- •19.2.1.1 Pathophysiology
- •19.2.1.2 Clinical Characteristics
- •19.2.1.3 Epidemiology
- •19.2.2 Behcet’s Disease
- •19.2.2.1 Clinical Characteristics
- •19.2.2.2 Pathogenesis
- •19.2.2.3 Diagnosis
- •19.2.2.4 Epidemiology
- •19.2.3 Thromboangiitis Obliterans
- •19.2.3.1 Diagnosis and Clinical Characteristics
- •19.2.3.2 Treatment
- •19.2.4 Temporal Arteritis
- •19.2.4.1 Epidemiology
- •19.2.4.2 Pathogenesis
- •19.2.4.3 Ocular Manifestations
- •19.2.5 Wegener’s Granulomatosis
- •19.2.5.1 Pathogenesis
- •19.2.5.2 Ocular Manifestation
- •19.2.5.3 Diagnosis
- •19.2.6 Kawasaki Disease
- •19.2.6.1 Clinical Characteristics
- •19.2.6.2 Diagnosis
- •19.3 Vascular Malformations
- •19.3.1.1 Diagnosis
- •19.3.1.2 Pathophysiology
- •19.4 Systemic Hypertension and Treatment
- •19.4.1 Etiology
- •19.4.1.1 Primary Hypertension
- •19.4.1.2 Secondary Hypertension
- •19.4.2 Pathophysiology
- •19.4.3 Pathology and Complications
- •19.4.4 Symptoms and Signs
- •19.4.5 Diagnosis of Hypertension
- •19.4.5.1 History
- •19.4.5.2 Physical Examination
- •19.4.5.3 Testing
- •19.4.6 Prognosis
- •19.4.7 General Treatment
- •19.4.7.2 Drugs
- •19.5 Hypertensive Retinopathy
- •19.5.2 Pathophysiology
- •19.5.3 Blood Pressure
- •19.5.3.1 The Risk of Stroke
- •19.5.3.2 The Risk of Coronary Heart Disease
- •19.5.4 Treatment
- •19.5.4.1 ACE Inhibitors and the Eye
- •References
- •Index
286 |
A. Reiner et al. |
|
|
|
|
180 |
|
|
|
Monkey |
|
|
|
|
|
|
|
|
|
|
|
160 |
|
|
|
c−wave |
|
|
|
|
|
|
b−wave |
|
|
|
|
|
|
|
|
|
|
ERG Amplitude |
|
140 |
|
|
|
|
|
(% of control) |
120 |
|
|
|
|
|
|
100 |
|
|
|
|
|
||
80 |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
60 |
|
|
|
|
|
|
|
40 |
|
|
80 |
100 |
120 |
|
|
20 |
40 |
60 |
Perfusion pressure (MAP−IOP in mmHg)
High IOP |
|
Normal IOP |
|
Fig. 12.27 Effect of ocular perfusion pressure on the c-wave and the b-wave of the ERG in cat, expressed as a percent of the control amplitude (Fig. 7 from [399]). The perfusion pressure was manipulated by increasing the IOP, which is known to reduce ChBF, with only modest
autoregulation by the choroid in response to the reduced perfusion pressure [169]. Note that with decreasing perfusion pressure, abnormalities in both the c-wave and the b-wave become evident, especially below a perfusion pressure of 60 mmHg
normally held in check by intact adaptive ciliary ganglion-mediated control of ChBF.
12.5.5Sympathetic Superior Cervical Ganglion Input
Sympathetic noradrenergic nerve Þbers from the superior cervical ganglion innervate the choroid in mammals [346] and birds [129]. In birds and mammals, the innervation is to blood vessels, and in birds to the smooth muscle of the choroidal stroma as well. Mammalian groups in which sympathetic innervation of the choroid has been demonstrated by catecholamine ßuorescence or immunolabeling include rats, guinea pigs, rabbits, cats, and monkeys (Fig. 12.28) [73, 89, 179, 201, 217, 359]. These nerve Þbers utilize noradrenaline as a neurotransmitter, and they thus contain the enzymes involved in its synthesis (such as tyrosine hydroxylase and dopamine beta-hydroxylase). The sympathetic nerve Þbers from the superior cervical ganglion travel to the choroid via orbital blood vessels or by joining the ophthalmic nerve [322]. Consistent with the sympathetic innervation of choroid and vessels sup-
plying the choroid, cervical sympathetic stimulation in rats, rabbits, cats, and monkeys increases uveal resistance and decreases ChBF (Figs. 12.10 and 12.29) [1, 6, 9, 10, 29, 291, 326]. The choroidal vasoconstriction caused by direct administration of noradrenaline or by activation of sympathetic nerves to the choroid is mediated by alpha-adrenergic receptors [1, 37, 114, 165, 183, 184, 326]. Kawarai and Koss [165] speciÞcally showed that alpha1-adrenoreceptors mediate sympathetic vasoconstriction in the rat choroid. Blockers of beta-adrenergic receptors, by contrast, have been shown in pig to be only marginally effective in dilating the short posterior ciliary arteries [44], and thus unlikely to have a signiÞcant vascular role in sympathetic choroidal control. The sympathetic co-transmitter NPY does, however, have a role in ChBF regulation, since intravenous NPY in rabbits decreases ChBF by 50% [254]. NPY may be responsible for that part of choroidal sympathetic vasoconstriction that is not blocked by alpha-adrenergic receptor antagonists [10]. NPY appears to particularly contribute to choroidal vasoconstriction with high sympathetic nerve Þring rates, and noradrenaline with low Þring rates [36].
12 Neural Control of Ocular Blood Flow |
287 |
|
|
Fig. 12.28 Images (a and b) show sympathetic nerve Þbers with varicosities in rat choroid immunolabeled for dopamine beta-hydroxylase (DBH). Images (c and d) show sensory
nerve Þbers with varicosities in rat choroid immunolabeled for substance P (SP). All images at the same magniÞcation arrows indicate labeled axons and terminals
Consistent with a role of alpha-adrenergic receptors in choroidal control, Kiel and Lovell [172] reported that alpha-adrenoreceptor block increased ChBF in rabbits, implying thus also a level of basal sympathetic tone in anesthetized rabbit choroid. Similarly, Chou et al. [52] reported ChBF increased at low ocular perfusion pressures in rabbit 1 week after sympathetic denervation of choroid. Such a manipulation also produced adrenergic supersensitivity [53]. Other investigators have, however, questioned the presence of signiÞcant basal sympathetic tone in ChBF at normal systemic blood pressure in awake animals [34, 37]. Consistent with this, Zhan et al. [416] reported that 24 h after sympathetic denervation ChBF was unchanged in rabbits Ð there was thus
no effect on resting tone. This issue was more extensively investigated by Chou et al. [54] in rabbits using LDF. They found that with reductions in perfusion pressure caused by increased IOP, ChBF remained stable until a perfusion pressure of <55 mmHg, at which point ChBF was proportional to perfusion pressure. In rabbits with either unilateral or bilateral cervical sympathectomy, ChBF declines were not as severe with extremely low perfusion pressure as in normal animals. Thus, sympathetic input does exert some tone on choroidal vessels that is evident at low perfusion pressures, at least in some species under some conditions.
Bill [37] has suggested that the sympathetic innervation of choroid becomes activated with
288 |
A. Reiner et al. |
|
|
a
ONL
INL
GCL
c
55KD
CL SNX
Mean Densitometry (% of contralateral)
b |
GFAP |
10 µm
150 |
|
d |
* |
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
100
50
0
CL |
SNX |
|
Treatments |
Fig. 12.29 Images and graphs showing retinal changes in rats after sympathectomy (From Steinle et al. [329]). Images (a and b) (Fig. 5 from [329]) show immunoßuorescent GFAP labeling in the contralateral (a) and sympathectomized (b) retina. Greater GFAP immunostaining is observed in MŸller cells in the sympathectomized retina. Images (c and d) (Fig. 6 from [329]) show representative results from a Western blot for GFAP protein levels
for control (CL) and sympathectomized (SNX) retina (c) and densitometric analysis of Western blot data for four pairs of control and sympathectomized retinas (d). In (d), the results are presented as a percent of control. The asterisk indicates a signiÞcant difference between experimental and control. GCL ganglion cell layer, INL inner nuclear layer, IPL inner plexiform layer. MagniÞcation the same in both (a and b)
high systemic blood pressure, serving to vasoconstrict the choroid to prevent the overperfusion that would otherwise occur with the increased perfusion pressure caused by the elevated systemic BP. Naturally occurring increases in systemic blood pressure can occur during stress or heightened activity levels. Sustained eleva-
tions of ChBF would cause increased IOP, breakdown of blood-retinal barriers, and edema and be harmful for retinal health and function. Such ocular overperfusion and/or vascular leakiness has, in fact, been demonstrated in sympathectomized rabbits with systemic blood pressure elevation caused by aortic clamping [30, 34] and in
12 Neural Control of Ocular Blood Flow |
289 |
|
|
sympathectomized monkeys subjected to systolic hypertension [79]. Several studies in humans have shown that the choroid vasoconstricts and thereby compensates for exercise-induced increases in systemic blood pressure [208, 292]. FuchsjŠger-Mayerl et al. [101] reported that endothelial release of the vasoconstrictor endothe- lin-1 plays a role in this effect. It may be that central baroreceptor-responsive circuitry acting via the sympathetic input to choroid contributes to choroidal baroregulation to high systemic BP. Longo et al. [207] noted, however, that orthostatic increases in ocular perfusion pressure caused by posture change (moving to a supine position) are not compensated for by choroidal vasoconstriction, as would be expected since such changes in perfusion pressure are not accompanied by increases in systemic pressure that would activate aortic baroreceptors.
Steinle et al. [328] investigated the consequences of loss of sympathetic tone on the rat choroid. They reported vascular remodeling after cervical sympathetic transection Ð choroidal arteries and veins were larger and more numerous than in normal rats. No changes in vessel abundance or ChBF were yet observed 2 days after the sympathetic transection, but by 6 weeks, vessels were much more numerous, vessel area was increased, and ChBF was fourfold increased. Steinle and Lashbrook [330] noted elevation of angiogenic factors in choroid after cervical sympathetic transection, and they suggested that these might contribute to increased vessel abundance. Vessel dilation might contribute to increased vessel size as well. Steinle et al. [329] noted that there was a signiÞcant reduction (30%) in photoreceptor cell numbers in sympathectomized rat eyes. This loss appeared to be due to apoptosis, since there was a doubling in apoptotic photoreceptor cell numbers after sympathectomy. The photoreceptor loss in sympathectomized eyes resulted in reduced width of the retinal outer nuclear layer. Increased MŸller cell immunostaining for GFAP spanning the ganglion cell layer and inner nuclear layer was also noted after sympathectomy (Fig. 12.29). These results suggest that loss of sympathetic innervation causes signiÞ-
cant changes to the physiology of the choroid that are adverse for retinal health.
12.5.6 Trigeminal Sensory Input
Sensory nerve Þbers from the trigeminal ganglion co-containing SP and CGRP innervate the choroid in mammals and birds (Fig. 12.28) [60, 318, 346]. These largely are branches of the ophthalmic nerve, but some that reach the orbit arise from the maxillary nerve. The sensory nerve Þbers typically join the meshwork of nerves behind the eye, with one prominent branch entering the ciliary ganglion (Fig. 12.10). Nerve Þbers reach the choroid by traveling with the short ciliary nerves and on blood vessels of the orbit. Among mammals, SP+ and CGRP+ Þbers to the choroid have been observed in rats [89], guinea pigs [193], monkeys [347], and humans [343, 347]. Sensory Þbers such as those of the trigeminal nerve send a central message of hot, cold, pain, or touch and can elicit ocular reßexes, such as blinking and tearing in response to their activation [23, 103]. It is possible that they also participate in temperature-dependent ChBF reßexes. Peripheral Þbers can also participate in antidromic responses in which they release SP and CGRP and cause local responses, which include a vascular component [23]. Consistent with an antidromic action of the SP+ input, rat and rabbit choroid possess SP receptors [68], and consistent with an antidromic action of the CGRP+ input, the choroid in pigs, guinea pigs, and monkeys has been shown to possess CGRP receptors [138]. The neuropeptides SP and CGRP are vasodilators, and their release from intrachoroidal trigeminal sensory Þbers would be expected to act on ChBF [35Ð37, 318, 346]. Consistent with this, stimulation of the ophthalmic nerve in rabbit increases ChBF [338] and is associated with uveal release of SP [34]. Orbital vessels too are sites at which sensory Þbers can affect the blood supply to the choroid. For example, Bakken et al. [17] showed that the pig ophthalmic artery dilates to CGRP. Additionally, trigeminal Þbers have SP+ and CGRP+ terminals in the PPG, which could be a basis of sensory-autonomic vascular
